Sotatercept: A novel therapeutic approach for pulmonary arterial hypertension through transforming growth factor-β signaling modulation

doi:10.5662/wjm.v15.i3.102688

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (53)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=46

Sep 20, 2025 (publication date) through Mar 6, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Methodology

ISSN

2222-0682

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Methodol. Sep 20, 2025; 15(3): 102688
Published online Sep 20, 2025. doi: 10.5662/wjm.v15.i3.102688

Sotatercept: A novel therapeutic approach for pulmonary arterial hypertension through transforming growth factor-β signaling modulation

Jyoti Bajpai, Mehul Saxena, Akshyaya Pradhan, Surya Kant

Jyoti Bajpai, Surya Kant, Department of Respiratory Medicine, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India

Mehul Saxena, Gandhi Memorial Hospital, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India

Akshyaya Pradhan, Department of Cardiology, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India

Author contributions: Bajpai J and Pradhan A conceptualized the idea and prepared the first draft; Saxena M and Kant S perform the literature search; Kant S and Bajpai J critically reviewed the draft and prose the changes; Bajpai J prepared the final manuscript and submitted; and all authors thoroughly reviewed and endorsed the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Jyoti Bajpai, MD, Department of Respiratory Medicine, King George’s Medical University, Shahmina Road, Chowk, Lucknow 226003, Uttar Pradesh, India. jyotibajpai33@gmail.com

Received: October 28, 2024
Revised: December 31, 2024
Accepted: January 11, 2025
Published online: September 20, 2025
Processing time: 131 Days and 22.7 Hours

Core Tip

Core Tip: Sotatercept is an activin receptor type IIA-Fc fusion protein that improve pulmonary artery pressure as well as cardiopulmonary function in pulmonary artery hypertension. It is administered as a subcutaneous injection every three weeks. There are three different pathways involve in pathogenesis of pulmonary arterial hypertension. Recently, a new pathway for pathogenesis of pulmonary arterial hypertension cellular proliferation has been discovered.